Profiles

Keywords
Last Name
Institution

Robin Jones

TitleAssistant Professor
InstitutionRush University, Rush Medical College
DepartmentObstetrics and Gynecology
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My NIH COMMONS name is RLJONES1.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Constantinidou A, Jones RL. Systemic therapy in retroperitoneal sarcoma management. J Surg Oncol. 2017 Nov 30. PMID: 29194633.
      View in: PubMed
    2. Pollack SM, Lu H, Gnjatic S, Somaiah N, O'Malley RB, Jones RL, Hsu FJ, Ter Meulen J. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. J Immunother. 2017 Oct; 40(8):302-306. PMID: 28891906.
      View in: PubMed
    3. Pollack SM, Lu H, Gnjatic S, Somaiah N, O'Malley RB, Jones RL, Hsu FJ, Ter Meulen J. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. J Immunother. 2017 Sep 18. PMID: 28926357.
      View in: PubMed
    4. Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol. 2017 Oct 20; 35(30):3433-3439. PMID: 28854066.
      View in: PubMed
    5. Jones RL, Thway K. Sarcoma: Does histotype-tailored neoadjuvant therapy improve outcomes? Nat Rev Clin Oncol. 2017 Oct; 14(10):589-590. PMID: 28786415.
      View in: PubMed
    6. Pender A, Jones RL. Olaratumab for the treatment of soft-tissue sarcoma. Future Oncol. 2017 Oct; 13(24):2151-2157. PMID: 28745071.
      View in: PubMed
    7. Mohamed M, Gonzalez D, Fritchie KJ, Swansbury J, Wren D, Benson C, Jones RL, Fisher C, Thway K. Desmoplastic small round cell tumor: evaluation of reverse transcription-polymerase chain reaction and fluorescence in situ hybridization as ancillary molecular diagnostic techniques. Virchows Arch. 2017 Nov; 471(5):631-640. PMID: 28748349.
      View in: PubMed
    8. Schneider N, Strauss DC, Smith MJ, Miah AB, Zaidi S, Benson C, van Houdt WJ, Jones RL, Hayes AJ, Fisher C, Thway K. The Adequacy of Core Biopsy in the Assessment of Smooth Muscle Neoplasms of Soft Tissues: Implications for Treatment and Prognosis. Am J Surg Pathol. 2017 Jul; 41(7):923-931. PMID: 28505003.
      View in: PubMed
    9. van Houdt WJ, Zaidi S, Messiou C, Thway K, Strauss DC, Jones RL. Treatment of retroperitoneal sarcoma: current standards and new developments. Curr Opin Oncol. 2017 07; 29(4):260-267. PMID: 28509807.
      View in: PubMed
    10. Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 Sep; 146(3):531-537. PMID: 28651804.
      View in: PubMed
    11. Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 Aug; 18(8):1089-1103. PMID: 28651927.
      View in: PubMed
    12. van der Graaf WTA, Jones RL. Neoadjuvant chemotherapy in localised soft-tissue sarcomas: where do we go from here? Lancet Oncol. 2017 Jun; 18(6):706-707. PMID: 28593841.
      View in: PubMed
    13. Szucs Z, Messiou C, Wong HH, Hatcher H, Miah A, Zaidi S, van der Graaf WT, Judson I, Jones RL, Benson C. Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs. 2017 Apr; 28(4):421-426. PMID: 28099210.
      View in: PubMed
    14. Thway K, Noujaim J, Thomas DM, Fisher C, Jones RL. Myoepithelial Carcinoma of the Paracecal Mesentery: Aggressive Behavior of a Rare Neoplasm at an Unusual Anatomic Site. Rare Tumors. 2017 Mar 24; 9(1):6504. PMID: 28458787.
      View in: PubMed
    15. Husson O, Jones RL. Q-TWiST: What really matters to the cancer patient? Cancer. 2017 Jun 15; 123(12):2200-2202. PMID: 28294292.
      View in: PubMed
    16. Lee AT, Pollack SM, Huang P, Jones RL. Phase III Soft Tissue Sarcoma Trials: Success or Failure? Curr Treat Options Oncol. 2017 Mar; 18(3):19. PMID: 28332083.
      View in: PubMed
    17. Noujaim J, Jones RL, Swansbury J, Gonzalez D, Benson C, Judson I, Fisher C, Thway K. The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. Br J Cancer. 2017 Feb 28; 116(5):669-678. PMID: 28141799.
      View in: PubMed
    18. Gronchi A, Maki RG, Jones RL. Treatment of soft tissue sarcoma: a focus on earlier stages. Future Oncol. 2017 Jan; 13(1s):13-21. PMID: 27918202.
      View in: PubMed
    19. Wilky BA, Jones RL, Keedy VL. The Current Landscape of Early Drug Development for Patients With Sarcoma. Am Soc Clin Oncol Educ Book. 2017; 37:807-810. PMID: 28561654.
      View in: PubMed
    20. Messiou C, Vanel D, Pollock R, Cooke M, Moskovic E, Savidge C, King L, Patel A, Jones RL. Dear John Hunter. BMJ. 2016 12 14; 355:i6515. PMID: 27974313.
      View in: PubMed
    21. Jones RL. Understanding sarcomas and other rare tumors: an interview with Robin L Jones. Future Oncol. 2017 Feb; 13(5):391-394. PMID: 27924638.
      View in: PubMed
    22. Thway K, Noujaim J, Jones RL, Fisher C. Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies. Ann Diagn Pathol. 2016 Dec; 25:64-71. PMID: 27806849.
      View in: PubMed
    23. Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, Ferrari S, Baldi GG, Jones RL, Chawla S, Casali P, LeCesne A, Blay JY, Dijkstra SP, Thomas DM, Rutkowski P. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res. 2016; 6(1):15. PMID: 27651889; PMCID: PMC5022265.
    24. Thway K, Noujaim J, Zaidi S, Miah AB, Benson C, Messiou C, Jones RL, Fisher C. Desmoplastic Small Round Cell Tumor: Pathology, Genetics, and Potential Therapeutic Strategies. Int J Surg Pathol. 2016 Dec; 24(8):672-684. PMID: 27621277.
      View in: PubMed
    25. Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J Clin Oncol. 2016 Sep 12. PMID: 27621408.
      View in: PubMed
    26. Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, Jones RL. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017 Jan; 13(1):93-107. PMID: 27600498.
      View in: PubMed
    27. Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, Jones RL. Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors. Future Oncol. 2017 Jan; 13(2):185-194. PMID: 27600625.
      View in: PubMed
    28. Ben Salha I, Zaidi S, Noujaim J, Miah AB, Fisher C, Jones RL, Thway K. Rare Aggressive Behavior of MDM2-Amplified Retroperitoneal Dedifferentiated Liposarcoma, with Brain, Lung and Subcutaneous Metastases. Rare Tumors. 2016 Sep 05; 8(3):6282. PMID: 27746879.
      View in: PubMed
    29. Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97. PMID: 27291997.
      View in: PubMed
    30. Mourtzoukou D, Zaidi S, Jones RL, Fisher C, Thway K. Soft Tissue Myoepithelial Carcinoma Metastatic to the Cecum: Highlighting an Unusual Metastatic Pattern and the Need for Diagnostic Awareness. Rare Tumors. 2016 Mar 21; 8(1):6086. PMID: 27134707; PMCID: PMC4827644.
    31. Lee ATJ, Huang PH, Pollack SM, Jones RL. Drug repositioning in sarcomas and other rare tumors. EBioMedicine. 2016 Apr; 6:4-5. PMID: 27211532; PMCID: PMC4856775.
    32. Noujaim J, Gonzalez D, Thway K, Jones RL, Judson I. p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib? Cancer Biol Ther. 2016 May 03; 17(5):543-5. PMID: 26942271; PMCID: PMC4910923 [Available on 03/04/17].
    33. Duffaud F, Maki RG, Jones RL. Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options. Expert Rev Clin Pharmacol. 2016 Feb 12. PMID: 26873304.
      View in: PubMed
    34. Thway K, Ng W, Noujaim J, Jones RL, Fisher C. The Current Status of Solitary Fibrous Tumor: Diagnostic Features, Variants, and Genetics. Int J Surg Pathol. 2016 Jun; 24(4):281-92. PMID: 26811389.
      View in: PubMed
    35. Thway K, Jones RL, Noujaim J, Zaidi S, Miah AB, Fisher C. Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies. Adv Anat Pathol. 2016 Jan; 23(1):30-40. PMID: 26645460.
      View in: PubMed
    36. Thway K, Jones RL, Noujaim J, Fisher C. Epithelioid Sarcoma: Diagnostic Features and Genetics. Adv Anat Pathol. 2016 Jan; 23(1):41-9. PMID: 26645461.
      View in: PubMed
    37. Noujaim J, Thway K, Fisher C, Jones RL. Dermatofibrosarcoma protuberans: from translocation to targeted therapy. Cancer Biol Med. 2015 Dec; 12(4):375-84. PMID: 26779374; PMCID: PMC4706526.
    38. Noujaim J, Thway K, Jones RL, Miah A, Khabra K, Langer R, Kasper B, Judson I, Benson C, Kollàr A. Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study. Anticancer Res. 2015 Nov; 35(11):6213-7. PMID: 26504053.
      View in: PubMed
    39. Noujaim J, Constantinidou A, Messiou C, Thway K, Miah A, Benson C, Judson I, Jones RL. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2015 Oct 29. PMID: 26523439.
      View in: PubMed
    40. Noujaim J, Thway K, Sheri A, Keller C, Jones RL. Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors. Int J Surg Pathol. 2016 Feb; 24(1):5-15. PMID: 26399578.
      View in: PubMed
    41. Jones RL, Bendell JC, Smith DC, Diefenbach K, Lettieri J, Boix O, Lockhart AC, O'Bryant C, Moore KN. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Oct; 76(4):777-84. PMID: 26281907.
      View in: PubMed
    42. Noujaim J, Thway K, Bajwa Z, Bajwa A, Maki RG, Jones RL, Keller C. Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. Front Oncol. 2015; 5:186. PMID: 26347853; PMCID: PMC4538302.
    43. Vlenterie M, Jones RL, van der Graaf WT. Synovial sarcoma diagnosis and management in the era of targeted therapies. Curr Opin Oncol. 2015 Jul; 27(4):316-22. PMID: 26049271.
      View in: PubMed
    44. Seddon B, Scurr M, Jones RL, Wood Z, Propert-Lewis C, Fisher C, Flanagan A, Sunkersing J, A'Hern R, Whelan J, Judson I. A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin Sarcoma Res. 2015; 5:13. PMID: 25987978; PMCID: PMC4434867.
    45. Attia S, Okuno SH, Robinson SI, Webber NP, Indelicato DJ, Jones RL, Bagaria SP, Jones RL, Sherman C, Kozak KR, Cortese CM, McFarland T, Trent JC, Maki RG. Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. Rare Tumors. 2015 May 05; 7(2):5992. PMID: 26266019; PMCID: PMC4508650.
    46. Noujaim J, van der Graaf WT, Jones RL. Redefining the standard of care in metastatic leiomyosarcoma. Lancet Oncol. 2015 Apr; 16(4):360-2. PMID: 25795407.
      View in: PubMed
    47. Jones RL, Sandri MT. Cardio-oncology: a special focus issue from Future Oncology. Future Oncol. 2015; 11(14):1993-4. PMID: 26198823.
      View in: PubMed
    48. Harris SJ, Benson C, Jones RL. Current and advancing systemic treatment options for soft tissue sarcomas. Expert Opin Pharmacother. 2015; 16(13):2023-37. PMID: 26255951.
      View in: PubMed
    49. Mhyre JM, D'Oria R, Hameed AB, Lappen JR, Holley SL, Hunter SK, Jones RL, King JC, D'Alton ME. The maternal early warning criteria: a proposal from the national partnership for maternal safety. Obstet Gynecol. 2014 Oct; 124(4):782-6. PMID: 25198266.
      View in: PubMed
    50. Chang AE, Chai X, Pollack SM, Loggers E, Rodler E, Dillon J, Parvathaneni U, Moe KS, Futran N, Jones RL. Analysis of clinical prognostic factors for adult patients with head and neck sarcomas. Otolaryngol Head Neck Surg. 2014 Dec; 151(6):976-83. PMID: 25257906.
      View in: PubMed
    51. Jones RL. Success is not final and failure is not fatal. J Clin Oncol. 2014 Oct 20; 32(30):3449-50. PMID: 25225429.
      View in: PubMed
    52. Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov R, Poondru S, Gedrich R, Lippman SM, Kaye SB, Carden CP. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res. 2015 Feb 15; 21(4):693-700. PMID: 25208878.
      View in: PubMed
    53. Mhyre JM, D'Oria R, Hameed AB, Lappen JR, Holley SL, Hunter SK, Jones RL, King JC, D'Alton ME. The maternal early warning criteria: a proposal from the national partnership for maternal safety. J Obstet Gynecol Neonatal Nurs. 2014 Nov-Dec; 43(6):771-9. PMID: 25203897.
      View in: PubMed
    54. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014 Feb 13; 6(3):514-27. PMID: 24462293; PMCID: PMC3928845.
    55. Martin-Liberal J, Alam S, Constantinidou A, Fisher C, Khabra K, Messiou C, Olmos D, Mitchell S, Al-Muderis O, Miah A, Linch M, Jones RL, Scurr M, Judson I, Benson C. Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma. Sarcoma. 2013; 2013:868973. PMID: 24369450; PMCID: PMC3867825.
    56. Jones RL, Ferrari S, Blay JY, Navid F, Lardelli P, Alfaro V, Siguero M, Soman N, Chawla SP. A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. Invest New Drugs. 2014 Feb; 32(1):171-7. PMID: 24173965.
      View in: PubMed
    57. Meyer JM, Perlewitz KS, Hayden JB, Doung YC, Hung AY, Vetto JT, Pommier RF, Mansoor A, Beckett BR, Tudorica A, Mori M, Holtorf ML, Afzal A, Woodward WJ, Rodler ET, Jones RL, Huang W, Ryan CW. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013 Dec 15; 19(24):6902-11. PMID: 24132922; PMCID: PMC3869565.
    58. Chang AE, Mann GN, Hoch B, Loggers ET, Pollack SM, Kolokythas O, Jones RL. Multiple liver abscess formation and primary gastrointestinal stromal tumor. Rare Tumors. 2013; 5(3):e51. PMID: 24179663; PMCID: PMC3804826.
    59. Constantinidou A, Miah A, Pollack S, Jones RL. New drugs and clinical trial design in advanced sarcoma: have we made any progress? Future Oncol. 2013 Oct; 9(10):1409-11. PMID: 23855285.
      View in: PubMed
    60. Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL. Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol. 2013 Jun; 30(2):501. PMID: 23456619.
      View in: PubMed
    61. Jones RL, Constantinidou A, Reis-Filho JS. Molecular Classification of Breast Cancer. Surg Pathol Clin. 2012 Sep; 5(3):701-17. PMID: 26838285.
      View in: PubMed
    62. Jones RL, Constantinidou A, Olmos D, Thway K, Fisher C, Al-Muderis O, Scurr M, Judson IR. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug; 35(4):351-7. PMID: 21422990.
      View in: PubMed
    63. Kilpatrick SJ, Prentice P, Jones RL, Geller S. Reducing maternal deaths through state maternal mortality review. J Womens Health (Larchmt). 2012 Sep; 21(9):905-9. PMID: 22621323.
      View in: PubMed
    64. Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012; 7(2):e32165. PMID: 22384167; PMCID: PMC3288075.
    65. Constantinidou A, Jones RL, Olmos D, Thway K, Fisher C, Al-Muderis O, Judson I. Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol. 2012 Apr; 51(4):550-4. PMID: 22023088.
      View in: PubMed
    66. Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D'Incalci M, Dei Tos AP, Raspagliesi F, Judson I, Casali PG. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol. 2011 Dec; 123(3):553-6. PMID: 21917307.
      View in: PubMed
    67. Jones RL, Constantinidou A, Thway K, Ashley S, Scurr M, Al-Muderis O, Fisher C, Antonescu CR, D'Adamo DR, Keohan ML, Maki RG, Judson IR. Chemotherapy in clear cell sarcoma. Med Oncol. 2011 Sep; 28(3):859-63. PMID: 20390470.
      View in: PubMed
    68. Olmos D, Martins AS, Jones RL, Alam S, Scurr M, Judson IR. Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations. Sarcoma. 2011; 2011:402508. PMID: 21647361; PMCID: PMC3103989.
    69. Jones RL, Rojo F, A'Hern R, Villena N, Salter J, Corominas JM, Servitja S, Smith IE, Rovira A, Reis-Filho JS, Dowsett M, Albanell J. Nuclear NF-?B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol. 2011 Feb; 64(2):130-5. PMID: 21148141.
      View in: PubMed
    70. Jones RL, Olmos D, Thway K, Fisher C, Tunariu N, Postel-Vinay S, Scurr M, de Bono J, Kaye SB, Judson IR. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemother Pharmacol. 2011 Aug; 68(2):423-9. PMID: 21069341.
      View in: PubMed
    71. Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K, Jones RL, Reis-Filho JS. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer. 2011 Jan; 47(1):138-50. PMID: 20832293.
      View in: PubMed
    72. Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Advanced aggressive fibromatosis: Effective palliation with chemotherapy. Acta Oncol. 2011 Apr; 50(3):455-61. PMID: 20799916.
      View in: PubMed
    73. Constantinidou A, Jones RL, Reis-Filho JS. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther. 2010 Aug; 10(8):1197-213. PMID: 20735307.
      View in: PubMed
    74. Lambros MB, Natrajan R, Geyer FC, Lopez-Garcia MA, Dedes KJ, Savage K, Lacroix-Triki M, Jones RL, Lord CJ, Linardopoulos S, Ashworth A, Reis-Filho JS. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol. 2010 Oct; 23(10):1334-45. PMID: 20543821.
      View in: PubMed
    75. Minchom A, Jones RL, Fisher C, Al-Muderis O, Ashley S, Scurr M, Karavasilis V, Judson IR. Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma. 2010; 2010:264360. PMID: 20508840; PMCID: PMC2874927.
    76. Olmos D, Tan DS, Jones RL, Judson IR. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 2010 May-Jun; 16(3):183-94. PMID: 20526094.
      View in: PubMed
    77. Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov; 45(17):2930-4. PMID: 19767198.
      View in: PubMed
    78. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(2):315-23. PMID: 19247830.
      View in: PubMed
    79. Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov; 6(10):1311-7. PMID: 19018683.
      View in: PubMed
    80. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009 Jul; 116(1):53-68. PMID: 18592370.
      View in: PubMed
    81. Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, Jones RL, Dowsett M, Mueller-Holzner E, Windbichler G, Daxenbichler G, Goebel G, Ensinger C, Jacobs I, Widschwendter M. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res. 2008 Jun 01; 14(11):3494-502. PMID: 18519782.
      View in: PubMed
    82. Tan DS, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008 Sep; 111(1):27-44. PMID: 17922188.
      View in: PubMed
    83. Savage K, Leung S, Todd SK, Brown LA, Jones RL, Robertson D, James M, Parry S, Rodrigues Pinilla SM, Huntsman D, Reis-Filho JS. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat. 2008 Jul; 110(2):245-56. PMID: 17912630.
      View in: PubMed
    84. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007 Jul; 8(7):595-602. PMID: 17586092.
      View in: PubMed
    85. Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 2007 Dec; 106(2):181-9. PMID: 17260090.
      View in: PubMed
    86. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CD, Schmitt FC, Ashworth A, Reis-Filho JS. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007 Jan 01; 13(1):90-101. PMID: 17200343.
      View in: PubMed
    87. Rodriguez-Pinilla SM, Jones RL, Lambros MB, Arriola E, Savage K, James M, Pinder SE, Reis-Filho JS. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol. 2007 Sep; 60(9):1017-23. PMID: 17158641; PMCID: PMC1972423.
    88. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2006 Nov; 5(6):791-809. PMID: 17044806.
      View in: PubMed
    89. Jones RL, Smith IE. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol. 2006 Oct; 7(10):869-74. PMID: 17012049.
      View in: PubMed
    90. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1249-69. PMID: 17020459.
      View in: PubMed
    91. Reis-Filho JS, Savage K, Lambros MB, James M, Steele D, Jones RL, Dowsett M. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol. 2006 Jul; 19(7):999-1009. PMID: 16648863.
      View in: PubMed
    92. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol. 2006 Feb; 19(2):307-19. PMID: 16424897.
      View in: PubMed
    93. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005 Dec; 41(18):2853-60. PMID: 16289617.
      View in: PubMed
    94. Jones RL, Judson IR. The development and application of imatinib. Expert Opin Drug Saf. 2005 Mar; 4(2):183-91. PMID: 15794712.
      View in: PubMed
    95. Jones RL, Miles DW. Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity. Lancet Oncol. 2005 Feb; 6(2):67. PMID: 15683815.
      View in: PubMed
    96. Jones RL, Berry GJ, Rubens RD, Miles DW. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol. 2004 Sep; 5(9):575-7. PMID: 15337488.
      View in: PubMed
    97. Jones RL, Cunningham D. Clinical and molecular prognostic factors in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer. 2003 Feb; 2(4):235-8. PMID: 12620143.
      View in: PubMed
    Jones's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description